Corcept Therapeutics Incorporated. (CORT)

Corcept Therapeutics' stock has been impacted by several events in the past six months. The Q3 2025 earnings report showed EPS exceeding expectations but revenue falling short, leading to lowered full-year guidance due to capacity constraints. The FDA's refusal to approve Relacorilant caused a significant stock decline. Positive Phase 3 ROSELLA trial results for relacorilant in ovarian cancer led to a stock increase. Insider selling has totaled $8,665,500.00 over the past three months. Analyst ratings average a "Hold" with an average twelve-month price target of $83.50.

Corcept experienced strong demand growth for its therapies, particularly Korlym, but has faced capacity constraints at its specialty pharmacy vendor, impacting revenue. Management anticipated fulfillment issues might continue into Q3 2025, with potential catch-up in Q4 2025 as pharmacy capacity expands. The company's ability to fully capitalize on demand may have periodic fluctuations tied to its supply chain and distribution capacity rather than inherent patient demand seasonality.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on discovering and developing medications for severe metabolic, oncologic, and neuropsychiatric disorders by modulating cortisol. Their primary product is Korlym, used to treat hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who also have type 2 diabetes or glucose intolerance and have failed or are not candidates for surgery. The company has a pipeline of selective cortisol modulators, including Relacorilant (Phase III for hypercortisolism and ovarian cancer), Dazucorilant (Phase II for ALS), and Miricorilant (Phase IIb for MASH), with other compounds in development for adrenal and prostate cancer.

Corcept Therapeutics Incorporated primarily operates in the United States, focusing on the discovery, development, and commercialization of pharmaceutical products. The company is headquartered in Redwood City, California.

Corcept Therapeutics' brand reputation has been negatively impacted by the FDA's refusal to approve relacorilant, leading to a stock price drop and investigations by securities-fraud law firms. Positive results from the ROSELLA trial provided some positive news, but the FDA decision has been a dominant factor.

Corcept Therapeutics has a mixed ownership structure. Institutional investors hold approximately 93.61% of the stock, with major holders including BlackRock, Inc. and Vanguard Group Inc. Insiders hold approximately 20.80% of the stock, with Patrick G. Enright being the largest individual shareholder.